|
 |
AltaceThis page contains recent news articles, when available, and an overview of Altace but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Overview: Altace (when available) Ramipril is an angiotensin-converting enzyme (ACE) inhibitor similar to benazepril, fosinopril, and quinapril. An inactive prodrug, ramipril is converted to ramiprilat in the liver and is used to treat hypertension and heart failure, to reduce proteinuria and renal disease in patients with nephropathies, and to prevent stroke, myocardial infarction, and cardiac death in high-risk patients. Indicated for diuretics and digitalis in congestive heart failure as adjunctive therapy; prophylaxis in post MI. Mechanism Of Action: Ramiprilat, the active metabolite, competes with angiotensin I for binding at the angiotensin-converting enzyme, blocking the conversion of angiotensin I to angiotensin II. As angiotensin II is a vasoconstrictor and a negative-feedback mediator for renin activity, lower concentrations result in a decrease in blood pressure and an increase in plasma renin. Ramiprilat may also act on kininase II, an enzyme identical to ACE that degrades the vasodilator bradykinin. News Articles on Ramipril Indian drug makers maintain pace of US marketing approvals - Jan 3, 2010 ...for generic versions of GlaxoSmithKline's Imitrex and Lamitcal, Johnson and Johnson's Topamax and Risperdal, King Pharma's Altace, Abbot's Depakote. ... Business Standard BC man gets licence for record number of marijuana plants - Dec 29, 2009 Drugs are drugs (Pharmaceutical) are drugs (Marijuana), no difference should be made between mainstream drugs such as Aspirin, Zocor, Altace etc.. or ... Examiner.com King Pharma 3Q Net Falls 48%, But Results Beat Views - Nov 5, 2009 King is still struggling to find a replacement for its once best-selling Altace blood-pressure treatment, whose sales have plunged due to generic ... Wall Street Journal Earnings Preview: King Pharmaceuticals - Nov 4, 2009 Negative trends for the company continue to include weakness in King's existing pipeline especially from Altace which is now off -patent. ... Seeking Alpha (blog) King Pharma Income Statement Analysis for September 2009 Quarter - Nov 9, 2009 Altace sales fell $19.8 million (66 percent), and sales of Thrombin-JMI declined 35 percent. Sales of Skelaxin, the company's biggest seller, were down 7.2 ... Seeking Alpha (blog) Medicare Drug Plans: Shop Around – You Can Save Thousands of Dollars a Year - Nov 10, 2009 The five drugs in the package are Altace 10mg (for high blood pressure), Celebrex 200mg (for arthritis type pain), Lipitor 10mg (for high cholesterol), ... Kansas City infoZine Dr Reddy's seeks US marketing rights for `Lipitor' generic - Nov 7, 2009 Ramipril (Altace - King), Venlafaxine (Effexor -Wyeth), Lamotrigine (Lamictal - Glaxo Smith Kline), and Levetiracetam (Keppra - UCB). ... domain-B Sanofi-aventis sees new opportunities in Quebec - Oct 22, 2009 ...tablets, liquids and creams, including such brands as Altace, Glucophage and Lasix as well as products for the company's dermatology division. ... The Gazette (Montreal) King Pharmaceuticals, Inc. - Pharmaceuticals & Healthcare - Deals and ... - Nov 9, 2009 The company's product line includes Avinza, CII Skelaxin, Thrombin-JMI, Altace, Levoxyl, Cytomel, Sonata, CIV Meridian and Auto injector Products/EpiPen. ... PR-Inside.com (Pressemitteilung) Brand Names/Synonyms: Altace is also known by the following brand names and/or synonymsAcovil; Altace; Carasel; Cardace; Delix; HOE 498; Hytren; Lostapres; Pramace; Quark; Ramace; Ramipril; Ramipril [Usan:Ban:Inn]; Ramiprilum [Latin]; Triatec; Tritace; Unipril; Vesdil Drug Category: Altace is categorized under the following by the FDA: Antihypertensive Agents; Angiotensin-converting Enzyme Inhibitors; ATC:C09AA05 Dosage Forms: CAPSULE Absorption: The extent of absorption is at least 50-60% and is not significantly influenced by the presence of food in the GI tract, although the rate of absorption is reduced. Interactions: [an error occurred while processing this directive] Chemical IUPAC Name: 4-[2-(1-ethoxycarbonyl-3-phenyl-propyl)aminopropanoyl]-4-azabicyclo[3.3.0]octane-3-carboxylicacid |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |
